OneTouch® Blood Glucose Meters are accurate, convenient and can make blood glucose testing less painful.* That's because we listen to customers and use this information to improve our products so people with diabetes can live a life without limits. In fact, OneTouch is the number one recommended brand by health care professionals. Whether you just need a test result, or you need more information to help you manage your diabetes, there's a OneTouch Blood Glucose Monitoring System that's right for you.

	The OneTouch® UltraMini® Meter offers testing made small and simple. Now available in four crowd-pleasing colors including Silver Moon, Limelight, Pink Glow and Black!
	The OneTouch® Ultra®2 Meter. A fast, gentle and simple way to help you see the effects of food on your blood glucose results.
	The OneTouch® UltraSmart® Meter is for people making insulin adjustments, and is the only blood glucose meter proven to help you lower A1C levels.†
	The OneTouch® UltraLink™ Meter wirelessly communicates to the MiniMed Paradigm® insulin pump, making bolus dosing easier and more accurate.**

LifeScan provides supplies and customer support for other OneTouch Meters:
OneTouch® Select™
OneTouch® Ultra®
InDuo® System
OneTouch® Basic®
OneTouch® SureStep®
OneTouch® FastTake®
OneTouch® Profile®

*Allows for a less painful stick when used with OneTouch® UltraSoft® Adjustable Blood Sampler and OneTouch® UltraSoft® Lancets.
† LifeScan data on file: Self-monitoring of blood glucose study number 1: The Ability of People with Diabetes to Use OneTouch* UltraSmart* to Improve Glycemic Control Through Behavioral and Therapeutic Changes (RPT 1039775, Nov. 2004) and Addendum #1 (Nov. 2005).

A 20-week, multicenter, randomized clinical trial compared adult and pediatric subjects with Type 1 and Type 2 diabetes and A1C = 8.0% , followed by a 46 week non-randomized observational study. Patients were randomized to use the OneTouch® UltraSmart® Meter (n=113) or conventional meters and paper logbooks (n=93). Both groups received monthly counseling from health care providers during the 20-week clinical trial and returned to usual care during the observational follow up. In the 20-week study, both groups saw a reduction in A1C; however, the reduction in the OneTouch® UltraSmart® Group was significantly greater (-0.6 vs. -0.4) (p = 0.03). In the observational study, subjects who chose to continue with the OneTouch UltraSmart Meter (n=42) showed a sustained reduction in A1C over subjects who chose to continue with conventional meters and paper logbooks (n=28), (8.47 vs. 9.25, p=0.006). The study did not evaluate whether this change in A1C will result in improved health outcomes.

**Compared to manual entry of blood glucose results.